Swiss reject genetic protection bill:
This article was originally published in Clinica
Swiss voters have rejected a proposal for a genetic protection bill which life science companies such as Roche and Novartis claim would have severely curtailed genetic research in Switzerland. According to press reports, the two companies spent around SFr35 million ($24.9 million) campaigning against the bill - other reports, however, put the figure at SFr8 million. The bill would have prohibited the patenting of products made using parts of genetically modified plants and animals, and the production and use of genetically modified animals.
You may also be interested in...
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.